Office of Infectious Diseases (OID)
The Office of Infectious Diseases (OID) consists of three review divisions: The Division of Anti-Infectives (DAI), the Division of Antivirals (DAV), and the Division of Pharm/Tox for Infectious Diseases (DPT-ID). The Immediate office oversees the development, review, and regulation of applications as well as issues related to toxicology for drug and biologic products reviewed in these divisions.
Immediate Office
Director: John Farley, M.D., MPH
Deputy Director: Adam Sherwat, M.D. (Acting)
Associate Director for Research: Thushi Amini, Ph.D.
Associate Director for Regulatory Science: Sunita Shukla, Ph.D., M.P.H.
Regulatory Operations
Director of Project Management Staff: Maureen Dillon-Parker (Acting)
Division of Anti-Infective (DAI)
Director: Sumathi Nambiar, M.D., M.P.H.
Deputy Director: Dmitri Iarikov, M.D., Ph.D.
Regulatory Operations
Chiefs of Project Management Staff: Maureen Dillon-Parker and Carmen DeBellas
Division of Antiviral (DAV)
Director: Debra Birnkrant, M.D.
Deputy Director: Jeffery Murray, M.D., M.P.H
Regulatory Operations
Chief of Project Management Staff: Karen Winestock
OID Research Activities
Overview of research needs, requests for information (RFIs), public workshops/meetings, opportunities for collaboration, externally awarded research studies, and other important research.
OID Regulatory Science Activities
Contact Us
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Infectious Diseases
10903 New Hampshire Avenue
Silver Spring, MD 20993
Phone: (301) 796-1300
Fax: (301) 796-9887
Resources For You
- OID Regulatory Science Activities
- Regulators in EU, Japan and US Take Steps to Converge on Approaches to Development of New Antibacterial Drugs
- FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria
- Antimicrobial Resistance Information for Consumers and Health Professionals
- Tropical Disease Priority Review Voucher Program
- OID Research Activities
- February 2018 HHS Report to Congress on Generating Antibiotic Incentives Now (GAIN)